Novel targets and derived small molecule inhibitors in multiple myeloma

Research output: Journal article (peer-reviewed)Review article

6 Citations (Scopus)


Recent research advances have defined a key role of the bone marrow (BM) in multiple myeloma (MM) pathogenesis thereby leading to new treatment paradigms, which aim to target both the tumor cell as well as its BM microenvironment. The incorporation of thalidomide, bortezomib, and lenalidomide into conventional cytotoxic and transplantation regimens in relapsed and refractory, but also in newly diagnosed MM has changed treatment options during the last decade. However, MM remains still incurable. Ongoing translational research aims to identify additional therapeutic targets and to design derived agents, predominantly small molecule inhibitors, with higher potency and less toxicity to further improve MM patient outcome and to overcome drug resistance.

Original languageEnglish
Pages (from-to)797-813
Number of pages17
JournalCurrent Cancer Drug Targets
Issue number7
Publication statusPublished - Sept 2012
Externally publishedYes


  • Animals
  • Antineoplastic Agents/pharmacology
  • Bone Marrow/drug effects
  • Clinical Trials as Topic
  • Drug Evaluation, Preclinical
  • Humans
  • Molecular Targeted Therapy/methods
  • Multiple Myeloma/drug therapy
  • Randomized Controlled Trials as Topic


Dive into the research topics of 'Novel targets and derived small molecule inhibitors in multiple myeloma'. Together they form a unique fingerprint.

Cite this